by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, clinical pharmacy specialist with Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD...
by Julian Guetta-Weiss, Chenyu Lin
As CAR T-cell therapy increasingly moves into the outpatient setting, remote digital monitoring technologies are helping clinicians detect toxicities earlier, enhance patient safety, and support...
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP and Mark Hamilton, MD, of The University of Texas MD Anderson Cancer Center discuss immune effector cell-associated...
by Alex Kadhim
New findings from the RESET-PV study suggest CD19 CAR-T therapy may be effective in pemphigus vulgaris without lymphodepleting chemotherapy, demonstrating clinical responses, B-cell depletion, and...
by Alex Kadhim
A comparative analysis of the FELIX trial suggests obecabtagene autoleucel (obe-cel) may improve remission rates, event-free survival, and overall survival compared with historical standard...
by Alex Kadhim
A comprehensive review from the ASTCT–NMDP ACCESS Initiative highlights persistent disparities in access to hematopoietic cell transplantation and CAR T therapy, revealing how race, age,...